Article
Thoracic radiotherapy synergizes with first-line EGFR-TKIs in advanced EGFR-mutant NSCLC: A dual-center real-world study.
International journal of cancer - 15 Apr 2026
Tian Zhuoying, Dai Shuang, Yang Xue, Zou Bingwen, Zeng Jingyuan, Luo Feng, Li Yan
Abstract excerpt
First-line thoracic radiotherapy (TRT) with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) shows promising efficacy in advanced EGFR-mutated non-small-cell lung cancer (NSCLC), yet clinical evidence remains limited. This dual-center retrospective study evaluated 322 patients receiving first-line EGFR-TKIs (197 first-/second-generation; 125 third-generation) between May 2017 and May 2024,...
Topics
Join the communities discussing this publication.
